Pertuzumab
- Generic Name
- Pertuzumab
- Brand Names
- Perjeta, Perjeta-Herceptin, Phesgo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 380610-27-5
- Unique Ingredient Identifier
- K16AIQ8CTM
- Background
Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. It was first approved by the FDA in 2012 for use with docetaxel and anoth...
- Indication
Pertuzumab is indicated for intravenous administration in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. It is also indicated in combination with trastuzumab and other chemotherapies for the neoadjuvant t...
- Associated Conditions
- Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
- Associated Therapies
- -
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-10-28
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 496
- Registration Number
- NCT02947685
- Locations
- 🇺🇸
University of Maryland - Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸The University of Chicago Medical Center, Chicago, Illinois, United States
A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-09-12
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 243
- Registration Number
- NCT02896855
- Locations
- 🇨🇳
the First Hospital of Jilin University, Changchun, China
🇨🇳Changzhou First People's Hospital, Changzhou, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai City, China
Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2016-06-03
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- Brown University
- Target Recruit Count
- 32
- Registration Number
- NCT02789657
- Locations
- 🇺🇸
Women and Infants hospital of RI, Providence, Rhode Island, United States
🇺🇸Rhode Island Hospital and The Miriam Hospital, Providence, Rhode Island, United States
A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)
- First Posted Date
- 2016-04-14
- Last Posted Date
- 2018-06-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 88
- Registration Number
- NCT02738970
- Locations
- 🇳🇿
Christchurch Clinical Studies Trust, Christchurch, New Zealand
🇳🇿Auckland Clinical Studies, Auckland, New Zealand
NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2018-09-28
- Lead Sponsor
- Midwestern Regional Medical Center
- Target Recruit Count
- 7
- Registration Number
- NCT02689921
- Locations
- 🇺🇸
Cancer Treatment Centers of America at Midwestern Regional Medical Center, Zion, Illinois, United States
🇺🇸Southeastern Regional Medical Center, Newnan, Georgia, United States
Denosumab as an add-on Neoadjuvant Treatment (GeparX)
- Conditions
- Interventions
- First Posted Date
- 2016-02-15
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- German Breast Group
- Target Recruit Count
- 780
- Registration Number
- NCT02682693
- Locations
- 🇩🇪
Charité Campus Mitte, Berlin, Germany
Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer
- First Posted Date
- 2015-12-09
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Helsinki University Central Hospital
- Target Recruit Count
- 516
- Registration Number
- NCT02625441
- Locations
- 🇫🇮
Helsinki University Central Hospital, Helsinki, Finland
Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-11-16
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 98
- Registration Number
- NCT02605915
- Locations
- 🇺🇸
HCA Midwest Division, Kansas City, Missouri, United States
🇺🇸Horizon Oncology Research, Inc., Lafayette, Indiana, United States
🇺🇸St. Luke's University Health Network, Bethlehem, Pennsylvania, United States
Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- Kimberly Blackwell
- Target Recruit Count
- 1
- Registration Number
- NCT02598427
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+
- Conditions
- Interventions
- First Posted Date
- 2015-11-01
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- Michelle Melisko
- Target Recruit Count
- 6
- Registration Number
- NCT02593708
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.